Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5585461A · kind A · utility
23Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 24, 1994 |
| Grant date | Dec 17, 1996 |
| Priority date | — |
| Expiry date | Mar 24, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/865
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.